Year: 2015-16
Company: Thermo Fisher Scientific
Liaison(s): Robert Shaw Craig Smith
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. The company’s mission is to enable its customers to make the world healthier, cleaner and safer. Thermo Fisher helps customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through its premier brands – Thermo Scientific®, Applied Biosystems®, Invitrogen®, Fisher Scientific® and Unity Lab Services® – the company offers an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. The BioProduction division at Thermo Fisher represents a rapidly growing business unit with a plethora of new project initiatives in the product development pipeline. The division seeks short and long-term solutions for balancing the risk and reward profile of the portfolio in order to facilitate double- digit organic revenue growth. The Thermo Fisher TMP team performed in-depth research and benchmarked best practices in portfolio management in order to help create a sustainable portfolio optimization plan. The team utilized project portfolio optimization literature and primary research interviews to construct customized portfolio models designed specifically for the BioProduction division business case. In addition, the team performed an evaluation of commercially available portfolio management software solutions with advanced capabilities. Through the deliverables of this project, the team has provided Thermo Fisher with a suite of tools that will allow the division to execute their corporate strategy with a monitored and analytical approach.